Drug Profile
Demcizumab - OncoMed Pharmaceuticals
Alternative Names: Anti-delta-like ligand 4 monoclonal antibody; Anti-DLL4 monoclonal antibody; OMP-18M21; OMP-21M18Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator OncoMed Pharmaceuticals
- Developer Celgene Corporation; OncoMed Pharmaceuticals
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action DLL4 protein inhibitors; Stem cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Colorectal cancer; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol Myers Squibb
- 24 Apr 2019 OncoMed Pharmaceuticals has been acquired by Mereo BioPharma
- 04 Nov 2017 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent) in New Zealand (IV, Infusion)